Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OneWorld Health (OWH) has completed enrollment in safety and efficacy study of Paromomycin Intramuscular Injection (PMIM) as a treatment for visceral leishmaniasis (VL or kala-azar) in Bangladesh.
Subscribe to our email newsletter
OWH’s effectiveness study, which enrolled 120 patients, is gathering information on how safe and efficacious PMIM mono-therapy for VL is at a regional level.
The study will also evaluate feasibility of PMIM mono-therapy for VL in the government health system in Bangladesh.
By conducting clinical trials at sites that are removed from urban centers, the study is expected to contribute to local capacity building for research and treatment of the disease.
OWH vice president and South Asia head Raj Ghosh said the company adopted a similar model for the trials in India, and are working to advance the treatment to Bangladesh.